Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study
The findings in the present real-world study reaffirm the clinical benefits and safety of the nivolumab plus cabozantinib combination across all subgroups, including populations that are generally excluded from clinical trials for whom data is often missing. Poor performance status, sarcomatoid de-differentiation, bone or central nervous system metastases and IMDC poor risk group were confirmed as negative prognostic factors.
Authors
- Sofía A. Méndez-Bribiesca
- Maria Teresa Bourlon (ORCID: https://orcid.org/0000-0002-3116-912X)
- Tarek Taha (ORCID: https://orcid.org/0000-0001-7936-5245)
- Ondřej Fiala (ORCID: https://orcid.org/0000-0002-4096-7385)
- Bohuslav Melichar (ORCID: https://orcid.org/0000-0002-5474-6866)
- Sebastiano Buti (ORCID: https://orcid.org/0000-0003-0876-0226)
- Dipen Bhuva (ORCID: https://orcid.org/0000-0002-8982-6209)
- Matteo Santoni (ORCID: https://orcid.org/0000-0001-7340-6173)
- Jakub Kucharz (ORCID: https://orcid.org/0000-0001-5388-8910)
- Luca Galli (ORCID: https://orcid.org/0000-0001-6008-0266)
- Marwan G. Ghosn (ORCID: https://orcid.org/0000-0003-1627-384X)
- Enrique Grande (ORCID: https://orcid.org/0000-0002-0134-4732)
- Vincenza Conteduca (ORCID: https://orcid.org/0000-0002-6921-714X)
- Javier Molina‐Cerrillo (ORCID: https://orcid.org/0000-0003-4616-0598)
- Aristotelis Bamias (ORCID: https://orcid.org/0000-0002-5996-7262)
- Ray Manneh Kopp (ORCID: https://orcid.org/0000-0002-8106-9741)
- Paola Valdez-Sandoval
- Alessia Salfi
- Francesco Massari (ORCID: https://orcid.org/0000-0001-6476-6871)
- Yüksel Ürün (ORCID: https://orcid.org/0000-0002-9152-9887)
- Fernando Sabino Marques Monteiro (ORCID: https://orcid.org/0000-0002-6621-8251)
- Ugo De Giorgi (ORCID: https://orcid.org/0000-0001-7520-2908)
- Teresa Alonso‐Gordoa (ORCID: https://orcid.org/0000-0002-8966-7236)
- Jawaher Ansari (ORCID: https://orcid.org/0000-0001-5525-548X)
- Gian Paolo Spinelli
- Pasquale Rescigno
- María José Juan-Fita
- Se Hoon Park
- Esther Pérez Calabuig
- Timothy Schieber
- Hussam Abu-Sini
Institutions
- University of Foggia (IT)
- University of Pisa (IT)
- University of Parma (IT)
- Royal Marsden NHS Foundation Trust (GB)
- Institute of Cancer Research (GB)
- Ankara University (TR)
- Saint Joseph University (LB)
- National and Kapodistrian University of Athens (GR)
- Charles University (CZ)
- Hospital Universitario Insular de Gran Canaria (ES)
- IMI TAMI Institute for Research and Development (IL)
- Samsung Medical Center (KR)
- Popular University of Cesar (CO)
- Eastern Cooperative Oncology Group (US)
- Tawam Hospital (AE)
- Institute of Cancer Research (CA)
- Ospedali Riuniti di Foggia (IT)
- The University of Kansas Cancer Center (US)
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
- Fundación Instituto Valenciano de Oncología (ES)
- University Hospitals Parma Medical Center (US)
- Associazione Italiana Di Oncologia Medica (IT)
- Azienda USL di Bologna (IT)
- National Institute of Oncology (HU)
- Hospital Sírio-Libanês (BR)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- MD Anderson Cancer Center Madrid (ES)
- Hospital Universitario Ramón y Cajal (ES)
- Haifa Medical Center (IL)
- Azienda Ospedaliera Universitaria Pisana (IT)
- Army Hospital Research and Referral (IN)
- University of Macerata (IT)
- Palacký University Olomouc (CZ)
- Newcastle University (GB)
- Universidad Panamericana (MX)
- University of Haifa (IL)
- University of Bologna (IT)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-07-25
- DOI
- https://doi.org/10.3389/fonc.2025.1605282
- Citations
- 4
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 6.07